REG - Kromek Group PLC - Director Share Purchase

KromekAnnouncement

03/11/2025 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251103:nRSC9315Fa&default-theme=true

RNS Number : 9315F  Kromek Group PLC  03 November 2025

3 November 2025

 

Kromek Group plc

("Kromek", the "Company" or the "Group")

 

Director Share Purchase

 

Kromek (AIM: KMK), a global detection company delivering best-in-class
solutions for the advanced imaging and CBRN detection markets, announces that,
on 31 October 2025, Matthew Boyle, Non-executive Director of the Company,
purchased 285,000 ordinary shares of 1p each in the Company ("Ordinary
Shares") at a price of 6.74p per Ordinary Share.

 

Following this transaction, Mr. Boyle holds 285,000 Ordinary Shares,
representing 0.04% of the Company's issued share capital.

 

 

Enquiries

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Claire Burgess, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Tim Redfern - ECM

 Michael Johnson - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury                                           +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

 In CBRN detection, the Group provides nuclear radiation detection solutions
to the global homeland defence and security market. Kromek's compact,
handheld, high-performance radiation detectors, based on advanced
scintillation and solid-state readout technology, are primarily used to
protect critical infrastructure, events, personnel and urban environments from
the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

Notification and public disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with them

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Matthew Boyle

 2    Reason for the notification

 a)   Position/status                                              Non-executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Kromek Group plc

 b)   LEI                                                          213800VLHYXGHEX5VQ48

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of 1 penny each

      Identification code                                          GB00BD7V5D43

 b)   Nature of the transaction                                    Purchase of ordinary shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     6.74p             285,000

 d)

      Aggregated information                                       N/A

      -      Aggregated volume

      -      Price

 e)   Date of the transaction                                      31 October 2025

 f)   Place of the transaction                                     London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBJBBTMTJMBBA



            Copyright 2019 Regulatory News Service, all rights reserved